23 May 2013
Keywords: Pfizer, Tofacitinib, Rheumatoid arthritis, Phase III trial, Patient deaths
Article | 26 April 2011
Global drugs behemoth Pfizer (NYSE: PFE) saw its share drop 3,6% to $19.67 after the company commented on an abstract concerning the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 April 2011
22 May 2013
© 2013 thepharmaletter.com